Abstract: Method of determining if a subject has suffered tissue damage from exposure to a toxic agent. The method comprises sequencing cell-free DNA (cfDNA) in a biospecimen from the subject; determining cellular origin of the cfDNA by identifying methylation patterns in one or more portions of the sequence of the cfDNA that contains methylation sites, in which the cellular origin of the cfDNA is determined when the methylation pattern in the one or more portions is the same as a known cell-type specific methylation patterns; measuring the quantity of the cfDNA of the determined cellular origin, and comparing the measured quantity of the cfDNA of the determined cellular origin with a normal quantity of cfDNA of the determined cellular origin. A greater quantity of the measured cfDNA of the determined cellular origin is indicative that the subject has suffered tissue damage.

Abstract: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.

Abstract: Methods for the treatment of cutaneous vascular conditions and cutaneous proliferative conditions are provided. The methods employ topical administration of mammalian target of rapamycin (mTOR) inhibitors such as sirolimus (rapamycin) and everolimus. Conditions treatable by the disclosed methods include venolymphatic malformations, acne, acne rosacea, periorificial dermatitis, acne vulgaris, cutaneous capillary malformation-arteriovenous malformation (CM-AVM) syndrome, RASopathies, Langerhans cell histiocytosis, non-Langerhans cell histiocytosis, scars, hypertrophic or keloidal scars, Proteus syndrome, PIK3CA-related overgrowth spectrum (PROS), PTEN hamartoma tumor syndromes, cutaneous malignancies and tumors associated with PI3K/AKT/mTOR mutations, keratodermas, acanthosis nigricans, Birt-Hogg-Dube syndrome, Brooke-Speigler syndrome, cylindromas, and epidermal nevi.

Abstract: The present invention provides methods of identifying neopeptides in abnormal cells, with the methods comprising sequencing long-read messenger RNA (mRNA) isolated from the abnormal cells, identifying splice variants that could be generated from the sequenced long-read mRNA, determining if the abnormal cells contain neopeptides that correlate with the identified splice variants. The methods may also comprise identifying at least one neoantigen on the neopeptides that are present in the abnormal cells.

Abstract: Technologies are described for reconstructing facial models which are preserved images or images captured from security cameras. The reconstructed models can be three-dimensional (3D) point clouds and can be compared to existing facial models and/or other reconstructed models based on physical geometry. The 3D point cloud models can be encoded into one or more latent space feature vector representations which can allow both local and global geometric properties of a face to be described. The one or more feature vector representations of a target face can be used individually or in combination with other descriptors for recognition, retrieval, and classification tasks. Neural networks can be used in the encoding of the one or more feature vector representations.

Abstract: Technologies are described for reconstructing physical objects which are preserved or represented in pictorial records. The reconstructed models can be three-dimensional (3D) point clouds and can be compared to existing physical models and/or other reconstructed models based on physical geometry. The 3D point cloud models can be encoded into one or more latent space feature vector representations which can allow both local and global geometric properties of the object to be described. The one or more feature vector representations of the object can be used individually or in combination with other descriptors for retrieval and classification tasks. Neural networks can be used in the encoding of the one or more feature vector representations.

Abstract: A method of detecting donor cell death in a subject receiving foreign biological material from a donor. The method comprises sequencing cfDNA in a biospecimen from the subject; determining cellular origin of the cfDNA by identifying methylation patterns in the sequence of the cfDNA and comparing the methylation patterns in the sequence of the cfDNA to known methylation patterns associated with different cell types; and determining source origin of the cfDNA by genotyping the cfDNA and identifying whether the cfDNA originates from the foreign biological material or from the subject. Cell death is detected when the cfDNA has both a cellular origin of the type of foreign biological material that was received from the donor, and a source origin of the donor.

Abstract: A method and system are described for improving the speed and efficiency of obtaining conversational search results. A user may speak a phrase to perform a conversational search or a series of phrases to perform a series of searches. These spoken phrases may be enriched by context and then converted into a query embedding. A similarity between the query embedding and document embeddings is used to determine the search results including a query cutoff number of documents and a cache cutoff number of documents. A second search phrase may use the cache of documents along with comparisons of the returned documents and the first query embedding to determine the quality of the cache for responding to the second search query. If the results are high-quality then the search may proceed much more rapidly by applying the second query only to the cached documents rather than to the server.

Abstract: A method that includes detecting the presence of a pancreatic intraepithelial neoplasia lesion in a subject in vivo comprising administering to the subject a construct, or a pharmaceutically acceptable salt thereof, wherein the construct comprises: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a detectable moiety complexed with, or conjugated to, the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.

Abstract: A flexible drug delivery patch is described for non-invasively delivering macromolecular drugs directly to the circulatory system of a user. The patch includes multiple sealed reservoirs formed therein, the sealed reservoirs containing the macromolecular drugs which are entrapped within one of a dissolvable polymer matrix using one of nanoparticles or nanofibers or a thermo-responsive hydrogel. The macromolecular drugs being released from the sealed reservoirs and the entrapping material by activating one or more electrically addressable microheating units.

Abstract: A method of treating cancer-related cognitive decline (CRCD) in a patient, in which the method comprises administering to the patient an effective amount of an inhibitor of receptor for advanced glycation endproducts (RAGE). The inhibitor of RAGE may be administered as a single dose or as multiple doses before the administration of the cancer therapy, during the administration of the cancer therapy, after the administration of the cancer therapy, or a combination thereof. Administration of the inhibitor of RAGE may improve attention, processing speed, executive functioning, learning, memory, or a combination thereof, of the patient as compared to patients who are not administered the inhibitor of RAGE.

Abstract: Provided herein are methods for treating fibrosis (e.g. pancreatic fibrosis) in a subject. Some methods comprise administering to a subject having pancreatic fibrosis an effective amount of a CCK receptor inhibitor.

Abstract: Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.

Abstract: Technologies are described for reconstructing facial models which are preserved images or images captured from security cameras. The reconstructed models can be three-dimensional (3D) point clouds and can be compared to existing facial models and/or other reconstructed models based on physical geometry. The 3D point cloud models can be encoded into one or more latent space feature vector representations which can allow both local and global geometric properties of a face to be described. The one or more feature vector representations of a target face can be used individually or in combination with other descriptors for recognition, retrieval, and classification tasks. Neural networks can be used in the encoding of the one or more feature vector representations.

Abstract: Embodiments of the present systems and methods may provide techniques for synthesizing speech in any voice in any language in any accent. For example, in an embodiment, a text-to-speech conversion system may comprise a text converter adapted to convert input text to at least one phoneme selected from a plurality of phonemes stored in memory, a machine-learning model storing voice patterns for a plurality of individuals and adapted to receive the at least one phoneme and an identity of a speaker and to generate acoustic features for each phoneme, and a decoder adapted to receive the generated acoustic features and to generate a speech signal simulating a voice of the identified speaker in a language.

Abstract: The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors.

Abstract: Novel ubiquitin specific protease 13 (USP13) inhibitors are provided, along with methods for their use. The USP13 inhibitors described herein are useful in treating and/or preventing USP13-related diseases, such as neurodegenerative diseases and cancer. Also provided are methods for inhibiting USP13 in a cell using the compounds and compositions described herein.

Abstract: The present invention provides methods of identifying neopeptides in abnormal cells, with the methods comprising sequencing long-read messenger RNA (mRNA) isolated from the abnormal cells, identifying splice variants that could be generated from the sequenced long-read mRNA, determining if the abnormal cells contain neopeptides that correlate with the identified splice variants. The methods may also comprise identifying at least one neoantigen on the neopeptides that are present in the abnormal cells.

Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.

Abstract: Provided herein is a method of treating medulloblastoma or glioblastoma in a subject by administering to the subject a PI3K activator (e.g., thymosin ?-4 or a derivative thereof) and one or more chemotherapeutic agents and/or radiation. The combination therapy is effective in the treatment of medulloblastoma or glioblastoma characterized by cells with elevated p53 levels.